3 active not recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression A2B530, xT-Onco with HLA-LOH Assay - Solid Tumor, Adult, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | A2 Biotherapeutics Inc. | 160 | 2023-04-28 | 2025-04-25 |
| HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study HBM4003, Toripalimab, Tislelizumab - Solid Tumors, Neuroendocrine Tumors | Phase 1 | Active not recruiting | Harbour BioMed (Guangzhou) Co. Ltd. | 53 | 2021-12-28 | 2025-04-27 |
| Study to Evaluate D-1553 in Subjects With Solid Tumors D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other - Solid Tumor, Adult, NSCLC | Phase 1 / Phase 2 | Active not recruiting | InventisBio Co., Ltd | 180 | 2020-10-02 | 2025-03-18 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Pancreatic Neoplasms (1) · Recurrence (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1)
Cetuximab (1) · pembrolizumab (1) · tislelizumab (1) · toripalimab (1)
A2 Biotherapeutics Inc. (1) · Harbour BioMed (Guangzhou) Co. Ltd. (1) · InventisBio Co., Ltd (1)
United States (2) · Australia (1) · China (1) · South Korea (1) · Taiwan (1)
Eric Ng, MD (1) · Lin Shen, Ph.D (1)